Indianapolis-based Elevance Health Inc. (ELV) is one of the largest U.S. health benefits and care management companies providing medical, pharmacy, dental, behavioral and care management services to government-sponsored and commercial members. With a market cap of $70.6 billion, Alliance operates nationally through its Blue Cross Blue Shield-affiliated health plans and its diversified healthcare services platform.
Companies valued at $10 billion or more are generally described as “large-cap stocks.” Elevation fits the bill perfectly. Its competitive strength lies in its unique Blue Cross Blue Shield franchises, which provide deep local market share, trusted branding, and extensive provider networks in multiple states. The foundation provides stable, recurring enrollment-driven revenue, bolstered by large participation in Medicaid and Medicare benefits.
Despite its considerable strength, ELV stock has fallen 30.3% from its 52-week high of $458.75 on April 8. Additionally, ELV has fallen 5.5% over the past three months, after the Dow Jones Industrial Average ($DOWI) rose 3.3% during the same time frame.
ELV stock is up 3.3% over the past six months and down 18.6% over the past 52 weeks, compared to the $DOWI’s 7.5% gain and 13.3% gain over the same time frames.
Shares of Altitude broke below their 50-day and 200-day moving averages in late January, indicating a bearish trend.
Shares of Allianz Health jumped 5.9% on Jan. 28 after a strong 2025 Q4 print that highlighted both growth momentum and cost pressures. Operating income rose 10% year-over-year to $49.3 billion, while adjusted EPS of $3.33 beat expectations, driven by premium rate increases, continued Medicare benefit expansion, and strong growth in the Carillon service platform.
Meanwhile, the industry’s top rival, Cigna Group ( CI ) is also facing challenges, with a 4.3% decline over the past 52 weeks and a 3.3% decline over the past six months.
Among the 21 analysts covering ELV stock, the consensus rating is “moderate buy”. The average price target of $383.31 suggests a potential upside of 19.8% from current price levels.
As of the date of publication, Kritika Sarma had no position (either directly or indirectly) in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. This article was originally published on Barchart.com
